Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of physician-diagnosed ragweed-induced allergic rhinoconjunctivitis of 2 years duration or more, with or without asthma~* Must have a positive skin prick test response to Ambrosia artemisiifolia~* Must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value~* Clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor~* Females of child-bearing potential must agree to use medically accepted methods of contraception~Exclusion Criteria:~* Unstable asthma or has experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids in previous 3 months~* Received an immunosuppressive treatment within 3 months~* History of anaphylaxis with cardio-respiratory symptoms.~* History of chronic urticaria or angioedema~* Current severe atopic dermatitis~* Female subject who is breastfeeding, pregnant, or intending to become pregnant~* Has received maintenance doses of immunotherapy with ragweed extract for ≥1 month within the last 5 years~* History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine~* Unable to or will not comply with the use of self-injectable epinephrine~* Participating in any other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCH 39641 12 Amb a 1-U (Type: EXPERIMENTAL): 12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet, sublingual, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).